Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study
Journal
Inflammatory bowel diseases
Journal Volume
29
Journal Issue
11
Date Issued
2023-11-02
Author(s)
Lin, Wei-Chen
Tai, Wei-Chen
Chang, Chung-Hsin
Feng, I-Che
Chung, Chen-Shuan
Yen, Hsu-Heng
Chou, Jen-Wei
Liu, Yu-Hwa
Huang, Tien-Yu
Chuang, Chiao-Hsiung
Tsai, Tzung-Jiun
Chiang, Feng-Fan
Lu, Chien-Yu
Hsu, Wen-Hung
Yu, Fang-Jung
Chao, Te-Hsin
Wu, Deng-Chyang
Ho, Ai-Sheng
Lin, Hung-Hsin
Feng, Chun-Lung
Wu, Keng-Liang
Wong, Ming-Wun
Lin, Chun-Chi
Chen, Chia-Chang
Hu, Huang-Ming
Lu, Lung-Sheng
Wang, Huann-Sheng
Wu, I-Chen
Kuo, Hsin-Yu
Yao Shih, Hsiang
Tang, Shu-Lun
Chen, Peng-Hsu
Abstract
This nationwide prospective registry study investigated the real-world effectiveness, safety, and persistence of vedolizumab (VDZ) in inflammatory bowel disease (IBD) patients in Taiwan. Disease relapse rates after VDZ discontinuation due to reimbursement restriction were assessed.
Subjects
Crohn’s disease; reimbursement; ulcerative colitis; vedolizumab
SDGs
Type
journal article